Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –
– Webcast may be accessed –

MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026.

The Company’s presentation is scheduled for Thursday, Feb 26 at 4:00-4:30 PM ET in Track 2, and the webcast may be viewed.

In addition to the presentation, management will be available for one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website. A replay will be available following the live event and will be archived for a limited time.

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

Forward Looking Statements